Skip to content

Ardelyx ARDX Deferred Tax Assets, Net of Valuation Allowance

Deferred Tax Assets, Net of Valuation Allowance at other companies

Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+25.5%
Enterprise value$1.71B+27.1%
P/S3.6×+0.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsNet.

The official record: Ardelyx’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's deferred tax assets, net of valuation allowance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's deferred tax assets, net of valuation allowance?
Ardelyx (ARDX) reported deferred tax assets, net of valuation allowance of $1.2M in Q4 2025.
How has Ardelyx's deferred tax assets, net of valuation allowance changed year-over-year?
Ardelyx's deferred tax assets, net of valuation allowance increased by 101.3% year-over-year, from $598K to $1.2M.
What is the long-term trend for Ardelyx's deferred tax assets, net of valuation allowance?
Over 5 years (2020 to 2025), Ardelyx's deferred tax assets, net of valuation allowance has grown at a 18.8% compound annual growth rate (CAGR), from $509K to $1.2M.